Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 174 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Breast Abnormalities Clear all
Withdrawn No phase listed Observational

Breast Cancer BRCA1 Carriers: a Pilot Study

NCT05062174
View directory record Official record
Conditions
BRCA1 Mutation, High-grade Serous Ovarian Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
Mifepristone 200 MG, Prophylactic mastectomy
Drug · Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Jun 11, 2026, 5:50 AM EDT
Terminated No phase listed Observational

Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer

NCT00949052
View directory record Official record
Conditions
Cancer
Interventions
DNA analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review, questionnaire administration, assessment of therapy complications, evaluation of cancer risk factors
Genetic · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Jun 11, 2026, 5:50 AM EDT
Completed No phase listed Observational

Follow-Up Study of People Treated for Scoliosis

NCT02546479
View directory record Official record
Conditions
Breast and Other Cancer Incidence and Mortality, All Cause Mortality, Circulatory Disease Mortality, Respiratory Disease Mortality
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
50 Years to 95 Years · Female only
Enrollment
5,573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2019 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Not applicable Interventional

Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

NCT00003538
View directory record Official record
Conditions
Cancer
Interventions
graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Jun 11, 2026, 5:50 AM EDT
Not listed Not applicable Interventional

Study of an Intervention to Improve Problem List Accuracy and Use

NCT01105923
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer, Coronary Artery Disease, Congestive Heart Failure, Diabetes, Glaucoma, Hemophilia, Hypertension, Hyperthyroidism, Hypothyroidism, Myasthenia Gravis, Osteoporosis, Osteopenia, Renal Failure, Renal Insufficiency, Sickle Cell Disease, Stroke
Interventions
MAPLE
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2015 · Synced Jun 11, 2026, 5:50 AM EDT
Terminated Early Phase 1 Interventional

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

NCT03185169
View directory record Official record
Conditions
Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections, Dyspareunia, Dysuria
Interventions
Replens and coconut oil
Combination Product
Lead sponsor
Alta Bates Summit Medical Center
Other
Eligibility
Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

NCT00600275
View directory record Official record
Conditions
Solid Tumors, Breast Cancer, Cowden Syndrome
Interventions
BGT226
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
4
States / cities
Boston, Massachusetts • Las Vegas, Nevada • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Jun 11, 2026, 5:50 AM EDT
Not listed No phase listed Observational

Women At Risk: The High Risk Breast Cancer Program

NCT01034891
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2009 · Synced Jun 11, 2026, 5:50 AM EDT
Terminated Phase 3 Interventional

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

NCT04869943
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Enobosarm, Exemestane
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
34
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Jun 11, 2026, 5:50 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Johns Hopkins Breast Cancer Program Longitudinal Repository

NCT01937039
View directory record Official record
Conditions
Breast Cancer, Benign Breast Disease
Interventions
Sample collection
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

NCT03056755
View directory record Official record
Conditions
Breast Cancer
Interventions
Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
25
States / cities
Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jun 11, 2026, 5:50 AM EDT
Terminated Phase 3 Interventional Results available

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

NCT01633060
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Fulvestrant, BKM120, BKM120 matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
37
States / cities
Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Jun 11, 2026, 5:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

NCT06993844
View directory record Official record
Conditions
Advanced Solid Tumors, Advanced Breast Cancer
Interventions
ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination with fulvestrant
Drug
Lead sponsor
Ensem Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Newport Beach, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Phase 1Phase 2 Interventional

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

NCT00064311
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
ravuconazole
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Jun 11, 2026, 5:50 AM EDT
Active, not recruiting Not applicable Interventional

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

NCT05677048
View directory record Official record
Conditions
Gynecologic Cancer, Ovary Cancer, Pancreatic Cancer, Breast Cancer, Lynch Syndrome, Hereditary Breast and Ovarian Cancer Syndrome, Colon Cancer, Endometrial Cancer, Uterus Cancer
Interventions
Free genetic testing and counseling group, IGNITE-TX Group, IGNITE-TX and free genetic testing and counseling group
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jun 11, 2026, 5:50 AM EDT
Recruiting Not applicable Interventional

The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI

NCT06892275
View directory record Official record
Conditions
Breast Neoplasm Female, Early Detection of Cancer, Hereditary Breast and Ovarian Cancer Syndrome, Magnetic Resonance Imaging
Interventions
Enhanced Usual Care, Decision Support
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 74 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Fresolimumab and Radiotherapy in Metastatic Breast Cancer

NCT01401062
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Fresolimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

Campath-1H + FK506 and Methylprednisolone for GVHD

NCT00109993
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
alemtuzumab, methylprednisolone, tacrolimus
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
New York, New York • Cleveland, Ohio • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Jun 11, 2026, 5:50 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members

NCT02194387
View directory record Official record
Conditions
Body Mass Index 25 or Greater, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Breast Carcinoma, Cancer Survivor, Chronic Lymphocytic Leukemia, Fatigue, Health Status Unknown, Lynch Syndrome, Ovarian Carcinoma, Overweight
Interventions
Dietary Intervention, Internet-Based Intervention, Laboratory Biomarker Analysis, Questionnaire Administration, Telephone-Based Intervention
Dietary Supplement · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jun 11, 2026, 5:50 AM EDT
Recruiting Phase 2 Interventional

Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

NCT05637216
View directory record Official record
Conditions
Radiation Induced Fibrosis
Interventions
Losartan 25 milligram capsule, Placebo
Drug
Lead sponsor
Shaw Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Edwards, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Evaluation of Stereoscopic Digital Mammography for Earlier Detection of Breast Cancer and Reduced Rate of Recall

NCT00208871
View directory record Official record
Conditions
Breast Cancer
Interventions
Stereoscopic Digital Mammography
Procedure
Lead sponsor
Emory University
Other
Eligibility
Female only
Enrollment
1,467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment

NCT03511690
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer
Interventions
BRCA-Gist
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Alexandria, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jun 11, 2026, 5:50 AM EDT
Completed Not applicable Interventional

A Comparison of the 15 and 30 Acquisition Angle Breast Tomosynthesis Mammography for Breast Abnormalities

NCT00990483
View directory record Official record
Conditions
Breast Cancer
Interventions
3D mammograpgy system
Device
Lead sponsor
Hologic, Inc.
Industry
Eligibility
40 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Jun 11, 2026, 5:50 AM EDT